This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Boehringer Ingelheim has announced that BI 695501, its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and FDA. 

×